JP6692358B2 - 転移性結腸直腸癌の抗血管新生療法に関連する予測的及び予後的バイオマーカー - Google Patents

転移性結腸直腸癌の抗血管新生療法に関連する予測的及び予後的バイオマーカー Download PDF

Info

Publication number
JP6692358B2
JP6692358B2 JP2017533704A JP2017533704A JP6692358B2 JP 6692358 B2 JP6692358 B2 JP 6692358B2 JP 2017533704 A JP2017533704 A JP 2017533704A JP 2017533704 A JP2017533704 A JP 2017533704A JP 6692358 B2 JP6692358 B2 JP 6692358B2
Authority
JP
Japan
Prior art keywords
vegf
patients
aflibercept
patient
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017533704A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017530372A (ja
JP2017530372A5 (enExample
Inventor
ニコール・ターシャ・シムズ
ボー・ガオ
イザレル・ロウィ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2017530372A publication Critical patent/JP2017530372A/ja
Publication of JP2017530372A5 publication Critical patent/JP2017530372A5/ja
Application granted granted Critical
Publication of JP6692358B2 publication Critical patent/JP6692358B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2017533704A 2014-09-16 2015-09-10 転移性結腸直腸癌の抗血管新生療法に関連する予測的及び予後的バイオマーカー Active JP6692358B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462051091P 2014-09-16 2014-09-16
US62/051,091 2014-09-16
US201562099630P 2015-01-05 2015-01-05
US62/099,630 2015-01-05
PCT/US2015/049279 WO2016044041A1 (en) 2014-09-16 2015-09-10 Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancer

Publications (3)

Publication Number Publication Date
JP2017530372A JP2017530372A (ja) 2017-10-12
JP2017530372A5 JP2017530372A5 (enExample) 2018-10-11
JP6692358B2 true JP6692358B2 (ja) 2020-05-13

Family

ID=54207741

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017533704A Active JP6692358B2 (ja) 2014-09-16 2015-09-10 転移性結腸直腸癌の抗血管新生療法に関連する予測的及び予後的バイオマーカー

Country Status (12)

Country Link
US (2) US10525104B2 (enExample)
EP (1) EP3194974B1 (enExample)
JP (1) JP6692358B2 (enExample)
KR (1) KR102471057B1 (enExample)
CN (1) CN107076749B (enExample)
AU (1) AU2015318207B2 (enExample)
CA (1) CA2960890A1 (enExample)
EA (1) EA036671B1 (enExample)
IL (1) IL250905B (enExample)
MX (1) MX382673B (enExample)
WO (1) WO2016044041A1 (enExample)
ZA (1) ZA201701664B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11699527B2 (en) 2013-03-14 2023-07-11 Otraces, Inc. Method for improving disease diagnosis using measured analytes
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2017117464A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
JP6952056B2 (ja) 2016-01-22 2021-10-20 オートレイシーズ, インク.Otraces, Inc. 疾患診断を改善するシステム及び方法
CA3058129C (en) * 2017-03-31 2023-04-18 Hirotsu Bio Science Inc. Method for predicting therapeutic effect and/or recurrence monitoring in cancer patients
US11524053B2 (en) 2018-01-26 2022-12-13 The Regents Of The University Of California Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents
BR112020017872A2 (pt) 2018-03-02 2020-12-22 Kodiak Sciences Inc. Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos
WO2020165483A1 (es) * 2019-02-15 2020-08-20 Universidad de Córdoba Método de predicción de respuesta a tratamiento del cáncer con agentes antiangiogénicos
JP2022541689A (ja) * 2019-07-13 2022-09-26 オートレイシーズ，インク． 腫瘍微小環境活性蛋白質を用いる種々の疾患の診断の改善
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021076852A1 (en) * 2019-10-17 2021-04-22 Board Of Regents, The University Of Texas System Small extracellular vesicle-associated vegf as a predictor for therapeutic responses
IL293131A (en) 2019-11-25 2022-07-01 Univ California Long-acting vegf inhibitors for intraocular neovascularization

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
CN101283280A (zh) * 2005-08-18 2008-10-08 Zadec私人有限公司 用于诊断结直肠癌的蛋白质标记和所述标记作为所述癌症类型治疗的药物靶点的用途
IN2012DN02046A (enExample) * 2009-08-14 2015-08-21 Allergan Inc
CN102711830A (zh) 2010-01-19 2012-10-03 霍夫曼-拉罗奇有限公司 用于贝伐单抗联合疗法的基于肿瘤组织的生物标志
SG10201505593VA (en) * 2010-07-19 2015-09-29 Hoffmann La Roche Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)

Also Published As

Publication number Publication date
EA036671B1 (ru) 2020-12-07
WO2016044041A1 (en) 2016-03-24
AU2015318207A1 (en) 2017-04-06
EA201790549A1 (ru) 2017-07-31
US10525104B2 (en) 2020-01-07
CN107076749B (zh) 2020-12-29
EP3194974B1 (en) 2019-10-23
MX382673B (es) 2025-03-13
ZA201701664B (en) 2018-05-30
MX2017003387A (es) 2018-01-30
JP2017530372A (ja) 2017-10-12
IL250905B (en) 2019-12-31
AU2015318207B2 (en) 2021-11-04
KR102471057B1 (ko) 2022-11-28
IL250905A0 (en) 2017-04-30
CA2960890A1 (en) 2016-03-24
KR20170055972A (ko) 2017-05-22
EP3194974A1 (en) 2017-07-26
CN107076749A (zh) 2017-08-18
US20200129589A1 (en) 2020-04-30
US20170281725A1 (en) 2017-10-05
US11439683B2 (en) 2022-09-13

Similar Documents

Publication Publication Date Title
JP6692358B2 (ja) 転移性結腸直腸癌の抗血管新生療法に関連する予測的及び予後的バイオマーカー
JP6055764B2 (ja) 乳癌の治療のためのベバシズマブ組合せ療法のための血漿バイオマーカー
AU2011281700B2 (en) Blood plasma biomarkers for bevacizumab combination therapies for treatment of pancreatic cancer
JP6057718B2 (ja) ベバシズマブ併用治療のための腫瘍組織に基づくバイオマーカー
JP6685276B2 (ja) 癌に罹患していることが疑われる患者のアフリベルセプトを用いた処置の結果を予測するための方法
JP2021527082A (ja) 新規な免疫チェックポイント阻害剤
Jiang et al. Peptide mimic isolated by autoantibody reveals human arrest defective 1 overexpression is associated with poor prognosis for colon cancer patients
CN108496084A (zh) 通过测量血浆生物标记的水平预测疑似患有癌症的患者使用阿柏西普的治疗的结果的方法
MX2013001523A (es) Neuroprolina como biomarcador para terapias combinadas de bevacizumab.
Shen et al. EphA2, vascular endothelial growth factor, and vascular endothelial growth factor correlate with adverse outcomes and poor survival in patients with glioma
EP3304086B1 (en) Method for predicting responsiveness to a combination therapy with lenvatinib and everolimus

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180830

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180830

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190626

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190709

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191009

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200317

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200414

R150 Certificate of patent or registration of utility model

Ref document number: 6692358

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250